Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
Medindia3d
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...
Applied Clinical Trials Online18h
Palatin Announces Results from Phase II Obesity Study of MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
The combination met its primary endpoint of percent weight loss following an 8-week treatment period.
Clinical Trials Arena on MSN5d
Palatin’s UC therapy prompts clinical remission in a third of patients
A third of patients with active ulcerative colitis (UC) experienced clinical remission in a Phase II trial of Palatin ...
Palatin says BMT-801 Phase 2 obesity study met primary endpoint
Technologies announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly ...
Yahoo Finance9d
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the US Food & Drug ...
The Pharma Letter2d
Palatin touts Phase II obesity study results
US drug developer Palatin Technologies (NYSE American: PTN) announced that its BMT-801 Phase II obesity co-administration ...
Morningstar6d
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Orally administered PL8177 is designed to target melanocortin-1 receptors on the surface of cells lining the colon. In a Phase 1 clinical trial, the oral version of PL8177 was shown to effectively ...
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...